Kintegral Advisory LLC Decreases Stake in Abbott Laboratories (NYSE:ABT)

Kintegral Advisory LLC decreased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 32.9% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 10,081 shares of the healthcare product maker's stock after selling 4,944 shares during the period. Kintegral Advisory LLC's holdings in Abbott Laboratories were worth $1,337,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Cim LLC boosted its position in shares of Abbott Laboratories by 0.4% in the fourth quarter. Cim LLC now owns 16,967 shares of the healthcare product maker's stock valued at $1,919,000 after acquiring an additional 73 shares during the period. Capital Square LLC raised its stake in Abbott Laboratories by 2.7% during the fourth quarter. Capital Square LLC now owns 2,941 shares of the healthcare product maker's stock worth $368,000 after acquiring an additional 77 shares in the last quarter. Consilium Wealth Advisory LLC raised its stake in Abbott Laboratories by 2.1% during the first quarter. Consilium Wealth Advisory LLC now owns 3,822 shares of the healthcare product maker's stock worth $507,000 after acquiring an additional 78 shares in the last quarter. Cyrus J. Lawrence LLC raised its stake in Abbott Laboratories by 9.0% during the fourth quarter. Cyrus J. Lawrence LLC now owns 954 shares of the healthcare product maker's stock worth $107,000 after acquiring an additional 79 shares in the last quarter. Finally, Edge Financial Advisors LLC increased its stake in shares of Abbott Laboratories by 3.3% in the first quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock valued at $336,000 after buying an additional 81 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Price Performance

NYSE ABT traded down $0.42 during trading hours on Friday, hitting $133.70. The company had a trading volume of 3,114,335 shares, compared to its average volume of 6,156,602. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $141.23. The firm has a 50 day simple moving average of $133.29 and a 200 day simple moving average of $128.41. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.27 and a current ratio of 1.78. The firm has a market capitalization of $232.61 billion, a price-to-earnings ratio of 17.34, a PEG ratio of 2.55 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.02. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%. Equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.77%. Abbott Laboratories's dividend payout ratio is 30.61%.

Wall Street Analyst Weigh In

Several brokerages recently commented on ABT. Bank of America upped their target price on Abbott Laboratories from $133.00 to $150.00 and gave the company a "buy" rating in a report on Monday, March 10th. Leerink Partners started coverage on Abbott Laboratories in a research report on Monday, June 16th. They set a "market perform" rating and a $143.00 target price on the stock. Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Barclays increased their price target on Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a research report on Thursday, April 17th. Finally, Royal Bank Of Canada raised their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research report on Thursday, April 17th. Six investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $142.61.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Sally E. Blount sold 2,600 shares of the firm's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the transaction, the director directly owned 34,058 shares of the company's stock, valued at approximately $4,415,960.28. This trade represents a 7.09% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.46% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.